Last reviewed · How we verify
Ecabet 3.70%
Ecabet 3.70% is a Gastroprotective agent Small molecule drug developed by Bausch & Lomb Incorporated. It is currently in Phase 2 development for Gastroprotection in patients with gastric ulcers.
Ecabet is a gastroprotective agent that acts as a mucosal protective agent.
Ecabet is a gastroprotective agent that acts as a mucosal protective agent. Used for Gastroprotection in patients with gastric ulcers.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Ecabet 3.70% |
|---|---|
| Sponsor | Bausch & Lomb Incorporated |
| Drug class | Gastroprotective agent |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 2 |
Mechanism of action
Ecabet works by enhancing the protective functions of the gastric mucosa, thereby reducing the risk of gastric ulcers and other gastrointestinal damage. It does this by increasing the production of prostaglandins, which help to maintain the integrity of the gastric mucosa.
Approved indications
- Gastroprotection in patients with gastric ulcers
Common side effects
- Headache
- Diarrhea
- Nausea
Key clinical trials
- Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome (PHASE2)
- Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ecabet 3.70% CI brief — competitive landscape report
- Ecabet 3.70% updates RSS · CI watch RSS
- Bausch & Lomb Incorporated portfolio CI
Frequently asked questions about Ecabet 3.70%
What is Ecabet 3.70%?
How does Ecabet 3.70% work?
What is Ecabet 3.70% used for?
Who makes Ecabet 3.70%?
What drug class is Ecabet 3.70% in?
What development phase is Ecabet 3.70% in?
What are the side effects of Ecabet 3.70%?
Related
- Drug class: All Gastroprotective agent drugs
- Manufacturer: Bausch & Lomb Incorporated — full pipeline
- Therapeutic area: All drugs in Gastrointestinal
- Indication: Drugs for Gastroprotection in patients with gastric ulcers
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing